Skip to main content

Teva Pharmaceutical Value Stock - Dividend - Research Selection

Teva pharmaceutical

ISIN: US8816242098 , WKN: 883035

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment\'s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


A Risky Spot For Corcept Therapeutics

2026-01-01

Here's What to Expect From Deckers Outdoor's Next Earnings Report

2025-12-30
Deckers Outdoor is scheduled to report its third-quarter results soon, and analysts expect a single-digit earnings decline.

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

2025-12-30
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, is pleased to announce the appointment of Dr. Olga Nissan as its Vice President of Business Development, effective as of January 1, 2026.

Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge

2025-12-30

What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)?

2025-12-30
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best affordable healthcare stocks to buy now. Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced on December 24 that S&P Global Ratings upgraded the company’s long-term issuer credit rating to ‘BB+’ from ‘BB’ with a stable outlook. Moody’s Ratings Agency also affirmed the company’s B1a rating, revising its outlook […]

This International Pharma Stock Just Hit 5-Year Highs

2025-12-26
Teva Pharmaceutical (TEVA) is trading at new 5-year highs. Shares are up more than 40% over the past year. The stock has strong technical momentum, maintaining a 100% “Buy” opinion from Barchart. TEVA offers international diversification and is favored by both Wall Street and individual investors. Today’s Featured Stock Valued...

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

2025-12-24
The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline.Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive from stableS&P upgraded Teva to BB+ from BB, with a stable outlook TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva’s long-term issuer credit rating to ‘BB+’ from ‘BB’, with a s

Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)

2025-12-23
Teva stock climbs past $30 with strong Austedo and Ajovy sales, but shifting Wall Street sentiment may affect its outlook.

Piper Sandler Maintains Teva Pharmaceutical Industries Limited - Depositary Receipt (TEVA) Overweight Recommendation

2025-12-23

J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play

2025-12-22
J&J has been trading above its 50- and 200-day SMAs for six months as strong 2025 execution, new drugs and pipeline progress support bullish momentum.